A federal court in New York has tossed a whistleblower lawsuit charging that large long-term care pharmacies violated the False Claims Act by failing to dispense requested generic drugs.
The nation's largest long-term care pharmacy has agreed to a $124 million settlement over claims of kickbacks to nursing homes in the form of price breaks on certain drugs, the U.S. Department of Justice announced Wednesday.
A whistleblower can pursue charges that long-term care pharmacy Omnicare ignored skilled nursing companies' overdue bills in exchange for certain kinds of business, a federal district court recently ruled.
MDI Achieve/MatrixCare announced it has achieved certification of integration with Omnicare using the NCPDP 10.6 standard, which will let clients reduce medication errors and increase efficiency.
Proper and effective medication management of controlled substances can save your facility thousands of dollars in needless waste and diversion. Most solutions are, figuratively speaking, right under your nose if you know where and how to look. Learn how to protect this valued asset, as well as your staff and residents.
A whistleblower can keep pursuing his allegations that long-term care pharmacy Omnicare funneled payments to nursing home owners through so-called charitable donations, U.S. District Court Judge Robert M. Dow Jr. recently ruled. Dow dismissed other charges leveled in the suit.
A recent $4 million legal settlement over kickbacks for anemia drug Aranesp is small change compared to other recent deals Omnicare has made with federal authorities. News of these payouts hasn't escaped long-term care pharmacy investors, some of whom filed their own charges against the pharmacy provider, launching a case that is now set to be heard by the U.S. Supreme Court.
The U.S. Supreme Court will hear a case alleging that the nation's largest long-term care pharmacy, Omnicare, broke the law by keeping potential investors in the dark about kickbacks to nursing homes, the high court announced Monday.
Omnicare, the nation's largest long-term care pharmacy, has reached a $4 million settlement agreement over allegations that the company conspired with a pharmaceutical company to switch nursing home residents to the anemia drug Aranesp, the U.S. Department of Justice announced Friday.
A whistleblower exposed disturbing drug packaging practices being used by long-term care pharmacy Omnicare Inc., but the charges don't fall under the False Claims Act, a federal appeals court recently ruled.
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement also will settle kickback charges related to the nation's largest long-term care pharmacy, Omnicare.
Two big reactions hit me when news of Johnson & Johnson's $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it's paying out and, second, some individual probably is going to cash a nice paycheck for bringing it all to light.
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes, the U.S. Department of Justice announced Monday. The agreement is one the largest ever of its kind, and will also settle charges that the companies paid kickbacks to the nation's largest long-term care pharmacy, Omnicare.
Omnicare, the nation's largest provider of long-term care pharmacy services, has agreed to pay $120 million to settle a False Claims Act lawsuit over Medicare Part A drug pricing, the company announced Wednesday. The settlement likely is one of the largest in a whistleblower case in which the government did not intervene, according to Frederick Morgan, one of Gale's attorneys at the firm Morgan Verkamp LLC.
Omnicare, the nation's largest long-term care pharmaceutical services provider, is positioned to be successful as insurance coverage expands under the Affordable Care Act, according to CEO John Workman.
Two former nursing home executives have agreed to pay $5 million to settle a whistleblower lawsuit involving long-term care pharmacy giant Omnicare Inc., according to the Chicago Tribune.
Kindred Healthcare will split with PharMerica and instead partner with Omnicare in 2014, marking a significant change in the landscape of long-term care pharmacy services providers.
A whistleblower who alleges Omnicare Inc. paid kickbacks to nursing homes did not violate the False Claims Act, a judge has ruled.
Two nursing home operators are set to stand trial to face whistleblower allegations that Omnicare Inc. paid them kickbacks during its purchase of Total Pharmacy.
An Illinois federal judge approved the dismissal of a whistleblower lawsuit against Omnicare, following a settlement agreement on July 9, according to local media reports.
Kindred Healthcare will split with pharmacy partner PharMerica and join forces with Omnicare at the end of 2013, according to documents filed with the Securities and Exchange Commission.
Major long-term care provider Kindred Healthcare will split with its current pharmacy partner, PharMerica, and team with the sector's largest pharmacy, Omnicare, at the end of 2013, according to documents filed with the Securities and Exchange Commission.
Omnicare has failed to disqualify a whistleblower who alleges the long-term care pharmacy paid kickbacks to nursing homes, ruled a district court judge.
Long-term care pharmacy Omnicare will not face charges that it engaged in "nationwide" Medicare fraud for off-label antipsychotics prescriptions, a federal judge recently ruled. However, the pharmacy still faces more limited False Claims Act charges over billing for antipsychotic drugs allegedly used for dementia care.
Biotechnology company Amgen will pay $24.9 million in a settlement over whistleblower allegations that the company paid kickbacks to long-term care pharmacies to increase the use of an anemia drug in nursing homes.
MDI Achieve announced that MatrixCare is now integrated with several leading pharmacy service firms. These include Omnicare, PharMerica, and FrameworkLTC.
With more vendors targeting the hospice market, two drug giants appear ready to face off. Walgreens left the institutional-pharmacy business in 2010, of which hospice pharmacy is a part, in a deal with Omnicare. Walgreens traded the unit for Omnicare's home-infusion business. Since then, Omnicare has been the market leader for hospice drugs. So why the strategy change for Walgreens?
The parent company of Golden Living officially launched AlixaRx with predictions it could become a $250 million per year business within 18 months.
Executives tied to one of the nation's largest nursing home chains say a new institutional pharmacy model they unveiled this week could soon become the market's No. 3 player. The parent group of Golden Living officially launched AlixaRx this week with predictions it could become a $250 million per year business within 18 months.
The headlines were big. Really big. And they involved a long-term care corporate giant settling yet another lawsuit. But they didn't tell the story I really wanted to know about. And that you probably want to know about, too.